MARKET

FRTX

FRTX

Fresh Tracks Therapeutics Inc
NASDAQ
2.050
+0.010
+0.49%
Pre Market: 2.080 +0.03 +1.46% 08:24 10/06 EDT
OPEN
2.080
PREV CLOSE
2.040
HIGH
2.095
LOW
1.920
VOLUME
1.80K
TURNOVER
--
52 WEEK HIGH
34.16
52 WEEK LOW
1.670
MARKET CAP
5.89M
P/E (TTM)
-0.1502
1D
5D
1M
3M
1Y
5Y
--Oppenheimer Adjusts Price Target on Fresh Tracks Therapeutics to $9 From $1, Maintains Outperform Rating
--Oppenheimer Adjusts Price Target on Fresh Tracks Therapeutics to $9 From $1, Maintains Outperform Rating
MT Newswires · 09/27 08:49
Fresh Track Therapeutics Says Board Appointed Deepak Chadha, Co.'s Chief Research & Development Officer, To Additional Position Of Chief Operating Officer; Says Andrew D. Sklawer, Co.'s President, Chief Operating Officer Will Remain President Of Co.
-Reuters
Benzinga · 09/20 20:54
BRIEF-Fresh Tracks Therapeutics Says Board Appointed Deepak Chadha, Co's Chief Research & Development Officer, To Additional Position Of Chief Operating Officer
BRIEF-Fresh Tracks Therapeutics Says Board Appointed Deepak Chadha, Co's Chief Research & Development Officer, To Additional Position Of Chief Operating Officer
Reuters · 09/20 20:53
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.
Benzinga · 09/13 16:32
Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion Of Phase 1 Study Of DYRK1A Inhibitor FRTX-02
FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing   On track to report SAD and MAD topline results from FRTX-02 Phase 1 study
Benzinga · 09/13 12:09
Fresh Tracks Therapeutics Begins Multiple Ascending Dose Portion of Inflammatory Disease Trial; Shares Rise
Fresh Tracks Therapeutics Begins Multiple Ascending Dose Portion of Inflammatory Disease Trial; Shares Rise
MT Newswires · 09/13 11:03
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 09/12 12:29
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Investor Place · 09/12 11:31
More
About FRTX
Fresh Tracks Therapeutics, Inc., formerly Brickell Biotech, Inc., is a clinical-stage pharmaceutical company engaged in transforming patient lives through the development of differentiated prescription therapeutics. Its pipeline is focused on providing existing treatment paradigms and features several new molecular entities that inhibit novel targets with potential for autoimmune, inflammatory, and other debilitating diseases. The Company’s strategy is exploring therapies by identifying, pursuing, and developing therapeutics that can help people struggling with autoimmune, inflammatory and other debilitating diseases. Its pipeline includes FRTX-02, FRTX-10, Kinase Inhibitors and FRTX-03. Its lead program, FRTX-02, is a clinical-stage oral DYRK1A inhibitor for patients with autoimmune diseases to be administered in humans. Its FRTX-10 is a preclinical-stage stimulator of interferon genes (STING) inhibitor candidate. Its Kinase Inhibitors include compounds that inhibit prominent targets.

Webull offers kinds of Fresh Tracks Therapeutics Inc stock information, including NASDAQ:FRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FRTX stock methods without spending real money on the virtual paper trading platform.